Page 8 - Randomized Phase News Today

WALTHAM, Mass., Sept. 30, 2022 -- Apellis Pharmaceuticals, Inc. , a global biopharmaceutical company and leader in complement, today announced that four oral presentations of data from the Phase 3... | September 30, 2022

The 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO) will take place October 23-26, at the Henry B. Gonzalez Convention Center in San Antonio, TX. The Annual Meeting delivers the top scientific and educational programming related to the field of radiation oncology.

The 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO) will take place October 23-26, at the Henry B. Gonzalez Convention Center in San Antonio, TX. The Annual Meeting delivers the top scientific and educational programming related to the field of radiation oncology.

Press release content from Business Wire. The AP news staff was not involved in its creation.

European Commission approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the treatment of multiple types of cancer ·         Vegzelma™ offers European patients living with certain types of breast, lung, renal, colon, rect...

Dr. Nuyten will oversee Arcus’s clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceu...

/PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free...

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye disease (DED). CyclASol has demonstrated in tw...

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, "Eisai") announced today that the company will present research from its Alzheimers...